Fish Oil and Hemodialysis Graft Patency: Does Time Matter?

Extract

More than 600 000 patients in the United States have end-stage kidney disease, with the majority—nearly 400 000 patients—requiring long-term maintenance hemodialysis.1 Ready access to the bloodstream is essential for hemodialysis and may be provided by a surgically created arteriovenous fistula, arteriovenous graft, or central venous catheter.2,3 An arteriovenous fistula is preferred because of its lower risk of thrombosis and lower overall cost. However, delayed maturation and failure rates of 20% to 60% for new fistulas result in greater reliance on catheters, the least desirable type of hemodialysis access.2,3 Compared with a new fistula, an arteriovenous graft is easier to cannulate and can be used within a few weeks of surgical creation. Yet grafts are associated with a higher rate of thrombosis, with attendant increased morbidity and cost. Grafts were once the most common type of hemodialysis access in the United States. However, through the efforts of the Fistula First Initiative, the End-Stage Renal Disease Networks, and the medical community, the prevalence of grafts in the United States has recently declined to less than 25%.4 Given the challenges of fistula maturation, grafts remain an appealing option, if the problem of thrombosis can be solved.

First Page Preview

Figures

Tables

References

Letters

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with
the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.

This feature is provided as a courtesy. By using it you agree that that you are requesting the material solely for personal, non-commercial use, and that it is subject to the AMA's Terms of Use. The information provided in order to email this article will not be shared, sold, traded, exchanged, or rented. Please refer to The JAMA Network's Privacy Policy for additional information.

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.